Drug Profile
CY 19
Alternative Names: CY19Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Overseas Pharmaceuticals
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Pain in China (Controlled release)
- 13 Feb 2018 Overseas Pharmaceuticals has patent protection for U-trol® technology (Overseas Pharmaceuticals website) before February 2018
- 13 Feb 2018 Preclinical trials in Pain in China (unspecified route)